Business
RenovoRx to Participate in AlphaNorth Capital Event, January 16-18, 2026
CEO Shaun Bagai to Discuss RenovoRx’s Commercial and Clinical Program ProgressMOUNTAIN VIEW, Calif., Jan. 14, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (Nasdaq: RNXT) (“RenovoRx” or “the Company”), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-cleared drug-delivery device, today announced that Chief Executive Officer Shaun Bagai will participate in the AlphaNorth Capital Event. The conference will be held from January 16-18,
About this update from Renovorx, Inc.
[{"type":"image","alt":"RenovoRx, Inc.","displaySize":"","headline":null,"caption":"RenovoRx, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":47,"url":"https://media.zenfs.com/en/globenewswire.com/ab41ac143cad3cd5a5d7e95f545a721c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/PIkpg_5WC5Ht6PAvrhd3Kg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTY2O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/ab41ac143cad3cd5a5d7e95f545a721c","width":300,"height":47}},"lazy":false},{"type":"text","content":"CEO Shaun Bagai to Discuss RenovoRx’s Commercial and Clinical Program Progress","length":78,"tagName":"p"},{"type":"text","content":"MOUNTAIN VIEW, Calif., Jan. 14, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (Nasdaq: RNXT) (“RenovoRx” or “the Company”), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-cleared drug-delivery device, today announced that Chief Executive Officer Shaun Bagai will participate in the AlphaNorth Capital Event. The conference will be held from January 16-18, 2026.","length":433,"tagName":"p"},{"type":"text","content":"Mr. Bagai will share an update on RenovoRx’s commercial progress, fueled by increasing demand for RenovoCath® as a standalone targeted drug-delivery device. Adoption is growing among both new and returning customers, including top cancer centers, highlighting the expanding need for localized, targeted treatment made possible through RenovoRx’s proprietary Trans-Arterial Micro-Perfusion (TAMP™) therapy platform.","length":414,"tagName":"p"},{"type":"text","content":"He will also discuss RenovoRx’s ongoing Phase III TIGeR-PaC clinical trial evaluating intra-arterial gemcitabine (IAG) delivered via RenovoCath in patients with locally advanced pancreatic cancer (LAPC), along with its post-marketing observational registry designed to collect real-world safety and survival data across solid tumors. In addition, Mr. Bagai will highlight RenovoRx’s support of capital-efficient, investigator-initiated trials in borderline resectable and metastatic pancreatic cancer, which may further expand the clinical utility of the TAMP™ therapy platform.","length":578,"tagName":"p"},{"type":"text","content":"AlphaNorth Capital Event Details:Date: January 16-18, 2026Location: Grand Hyatt Baha Mar, Nassau, Bahamas","length":107,"tagNa...